Changzhou Kaiqiao Biotechnology Co.,Ltd

Telephone:

+86-180-38176818

Eptifibatide Acetate Antiplatelet Drug
Eptifibatide Acetate Antiplatelet Drug

Eptifibatide Acetate Antiplatelet Drug

Contact : Mr.Thyen-------------------------------- Email us at zhangyinglong@ycphar.com Whatsapp : +86 180 3817 6818

Send Inquiry

  • Product Details

Eptifibatide Acetate

 

Contact : Mr.Thyen

Email us at zhangyinglong@ycphar.com

Whatsapp : +86 180 3817 6818


Cas No:148031-34-9

Name: Eptifibatide Acetate, eptifibatida, Eptifibatid
Formula: C37H53N11O11S2
Molecular:892
Sequence:3-MERCAPTOPROPIONYL-HOMOARG-GLY-ASP-TRP-PRO-CYS-NH2 ACETATE SALT (DISULFIDE BOND)
Purity:98%
Appearance: white powder
Source: synthetic

 

What is Eptifibatide Acetate ?

Eptifibatide is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.

Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.

Integrilin is sold in two strengths, globally: vials containing 2 mg/ml (20 mg totally) and 0.75 mg/ml (75 mg totally). A third size is sold in the US: 100 ml vials containing 2 mg/ml (200 mg totally).


Eptifibatide Acetate Application

1. Eptifibatide Acetate is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).

2. Eptifibatide Acetate is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.

3. Eptifibatide Acetate should exclusively be used in hospitalized patients both because of the serious degree of patients’ illness and because of the possible side-effects of eptifibatide.

 

Eptifibatide Acetate Dosage

The recommended adult dosage is an i.v. loading dose of 180 µg/kg over 1 to 2 minutes immediately after diagnosis, followed by continuous i.v.-infusion of 2 µg/kg per minute until either hospital discharge or initiation of coronary artery bypass grafting, or for up to 72 hours. At least 4 hours before discharge all local or systemic bleedings should have been controlled and terminated.

Patients weighing >120 kg should receive a maximum bolus of 22.6 mg followed by a maximum infusion rate of 15 mg/h. Patients with renal impairment evidenced by CrCl <50 ml/min should receive the standard 180 µg/kg loading dose followed by infusion at 1 µg/kg/min.


Hot Tags: eptifibatide acetate antiplatelet drug, China, suppliers, manufacturers, wholesale, buy, price
Related Products
  • Feedback